Biotechnology News

WATERTOWN, Mass., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Kestrel Therapeutics Inc. (“Kestrel” or the “Company”), a clinical-stage biotechnology company developing next-generation small-molecule...

Proceeds to support continued clinical development of ontivatrep, an oral TRPV3 inhibitor, with Phase 1b topline results in Olmsted syndrome expected by the end of 2026 NESS ZIONA, Israel, Sept. 15,...

Statistically significant benefits observed in bezisterim-treated Long COVID patients in pre-specified subgroups with high baseline fatigue, cognitive impairment, and/or post‑exertional malaise ...

SAN DIEGO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Axiom Biosciences, a clinical-stage biotechnology company developing next-generation regenerative therapies and targeted biologics, today announced a...

● PDUFA Target Action Date Set for March 16, 2027 SALT LAKE CITY, Sept. 15, 2026 (GLOBE NEWSWIRE) -- PolarityBio®, a late-stage biotechnology company addressing unmet needs in wound healing through...

TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative...

– Rademikibart meaningfully reduced the rate of treatment failure at 28 days by 66% compared to placebo – –Rademikibart produced a rapid, statistically significant improvement in lung function at Day...

- Daphne Karydas appointed as President and Chief Financial Officer - Weston Miller, MD, appointed as Chief Medical Officer - Additional appointments: Nina Hunter, PhD, as Chief Development Officer...

Walden Biosciences announces appointment of Rekha Abichandani, M.D., to CMO and upcoming clinical data for WAL0921 in proteinuric chronic kidney disease.

Berkeley, CA, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA) (the “Company”) announced today that on September 9, 2026, the Company received a letter (the “Compliance Determination...